CELL PATHWAYS SIGNS PALADIN FOR APTOSYN MARKETING IN CANADA.Cell Pathways, Inc. (Nasdaq:CLPA CLPA CC-Link Partner Association CLPA Club Loisirs et Plein Air (Montpellier, France) CLPA Child Labour Programme of Action (national plan to eliminate child labour in South Africa) ), Horsham, Pa., has signed a marketing and distribution agreement for Canada with Paladin Labs (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :PLB (Picture Level Benchmark) A benchmark for measuring graphics performance on workstations. The Benchmark Interface Format (BIF) defines the format, the Benchmark Timing Methodology (BTM) performs the test, and the Benchmark Reporting Format (BRF) generates results in ) of Montreal, Canada. The agreement provides Paladin Labs with exclusive rights to commercialize Aptosyn(TM) (exisulind) within Canada. The initial use of Aptosyn(TM) is expected to be for the treatment of precancerous precancerous /pre·can·cer·ous/ (-kan´ser-us) pertaining to a pathologic process that tends to become malignant. pre·can·cer·ous adj. colon polyps in patients with familial adenomatous polyposis familial adenomatous polyposis Familial polyposis An AD condition affecting ±50,000–US, characterized by progressive development of hundreds of adenomatous colorectal polyps; progression to cancer Molecular pathology APC (FAP (language) FAP - The assembly language for Sperry-Rand 1103 and 1103A. [Listed in CACM 2(5):16 (May 1959)]. ). The terms of the agreement were not disclosed. "Paladin has proven to be a leader in Canada in the commercialization of specialty medical products, with a strong track record of success in achieving regulatory approval and commercialization of innovative new drugs," said Robert Towarnicki, president and chief executive officer for Cell Pathways. "Paladin has also forged unique relationships with high prescribing physicians in a number of specialty markets. This should provide a strong foundation for marketing Aptosyn(TM) effectively, once Paladin achieves regulatory approval for the product in Canada." "Paladin is excited to be working with Cell Pathways on the commercialization of Aptosyn(TM), which has shown promise in a broad number of important precancer pre·can·cer n. A lesion from which a malignant tumor is presumed to develop in a significant number of instances and that may or may not be recognizable clinically or by microscopic changes in the affected tissue. and cancer indications," stated David MacNaughtan, Paladin's vice president, business development. "In addition to offering new hope for patients with FAP, Aptosyn(TM) has the potential to be a future great addition to our urology franchise for the treatment of prostate cancer." Aptosyn(TM) is currently under review by the Food and Drug Administration in the United States for the prevention and treatment of precancerous colon polyps in patients with FAP. Cell Pathways is also conducting clinical investigations with Aptosyn(TM), both as a single agent and in combination with traditional chemotherapeutic agents, for the treatment and prevention of a variety of other cancers and precancerous conditions. A second SAAND compound, CP 461, is completing Phase Ib clinical safety testing in cancer patients. Paladin Labs, headquartered in Montreal, Quebec, is a Canadian developer, marketer and distributor of innovative pharmaceuticals currently offering products in urology, dermatology, rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc. rheu·ma·tol·o·gy n. and other specialty markets. For more information about Paladin, please visit the Paladin Web Site at www.Paladin-labs.com or send e-mail to info@paladin-labs.com. Cell Pathways, Inc., headquartered in Horsham, is a development-stage pharmaceutical company focused on the research, development and commercialization of novel and unique medications to prevent and treat cancer. For additional information on Cell Pathways, Inc., visit the company's website at http://www.cellpathways.com or call 215/706-3800. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion